Quarterly ResultMay 7, 2026, 07:08 AM
Climb Bio Secures $110M Private Placement; Q1 R&D $9.4M
AI Summary
Climb Bio, Inc. reported its first quarter 2026 financial results and provided business updates. The company secured a $110 million private placement financing, significantly strengthening its balance sheet. For Q1 2026, R&D expenses were $9.4 million, down from $17.3 million in Q1 2025, while G&A expenses were $5.8 million. Climb Bio also provided updates on its budoprutug and CLYM116 programs, including robust B-cell depletion observed with budoprutug's subcutaneous formulation and anticipated data readouts for ongoing clinical trials in 2026.
Key Highlights
- Secured $110 million private placement financing on April 29, 2026.
- Cash, cash equivalents, and marketable securities were $146.3 million as of March 31, 2026.
- Cash balance expected to fund operations into 2028, excluding new financing.
- Q1 2026 R&D expenses were $9.4 million, down from $17.3 million in Q1 2025.
- Q1 2026 G&A expenses were $5.8 million, compared to $6.0 million in Q1 2025.
- Budoprutug SC formulation showed robust B-cell depletion in healthy volunteers.
- Budoprutug pMN, ITP, and SLE clinical trials are enrolling to plan.
- Initial budoprutug ITP data expected June 2026; pMN/SLE data in Q4 2026.
Price Impact
More from CLYM